News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Nektar Therapeutics Ovarian Cancer Drug Benefits Women in Study
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- About 48 percent of women with advanced ovarian cancer saw sustained benefits from treatment with Nektar Therapeutics' experimental drug NKTR-102 in a mid-stage study, the company said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Obesity
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
August 7, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market
August 6, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
August 5, 2025
·
3 min read
·
Dan Samorodnitsky
Neuroscience
Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial
August 5, 2025
·
2 min read
·
Tristan Manalac
